Mizuho Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $96
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $106 to $96.
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $106 to $96.